Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In a controlled clinical study, 304 patients were treated with testosterone gel 1% 50 mg or 100 mg or placebo gel for up to 90 days. Two hundred five (205) patients received testosterone gel 1% 50 mg or 100 mg daily and 99 patients received placebo. Subjects could be counted in both testosterone gel 1% treatment groups if they received both 50 mg and 100 mg at different points in the study and experienced an adverse reaction at both dose levels. Adverse reactions reported by ≥ 1% of the testosterone gel 1% patients and greater than placebo are listed in Table 1.
Table 1: Incidence of Adverse Reactions (Reported by ≥1% of the Testosterone Gel 1% Patients and Greater than Placebo) in the Controlled Clinical Trial Through 90 Days| Event | Testosterone Gel 1% | Testosterone Gel 1% | Placebo |
| 50 mg | 100 mg | |
| (n=103) | (n=149) | (n=99) |
Application Site
Reactions | 2% | 4% | 3% |
Blood Pressure
Increased | 1% | 1% | 0% |
| Gynecomastia | 1% | 0% | 0% |
| Headache | 1% | 1% | 0% |
| Hematocrit / hemoglobin Increased | 1% | 2% | 0% |
| Hot Flushes | 1% | 0% | 0% |
| Insomnia | 1% | 0% | 0% |
| Mood Swings | 1% | 0% | 0% |
| Smell Disorder | 1% | 0% | 0% |
| Spontaneous Penile Erection | 1% | 0% | 0% |
| Taste Disorder | 1% | 1% | 0% |
The following adverse reactions occurred in fewer than 1% of patients but were greater in testosterone gel 1% groups compared to the placebo group: activated partial thromboplastin time prolonged, blood creatinine increased, prothrombin time prolonged, appetite increased, sensitive nipples, and acne.
In this clinical trial of testosterone gel 1%, 6 patients had adverse reactions that led to their discontinuation. These events included: depression with suicidal ideation, urinary tract infection, mood swings and hypertension. No testosterone gel 1% patients discontinued due to skin reaction. In one foreign Phase 3 trial, one subject discontinued due to a skin-related adverse reaction.
In the pivotal US and European Phase 3 trials combined, at the 50-mg dosage strength, the percentage of subjects reporting clinically notable increases in hematocrit or hemoglobin were similar to placebo. However, in the 100-mg dose group, 2.3% and 2.8% of patients had a clinically notable increase in hemoglobin (≥ 19 g/dL) or hematocrit (≥ 58%), respectively, compared to 1.0% and 1.5% of patients in the placebo group, respectively.
In the combined US and European open-label extension studies, approximately 140 patients received testosterone gel 1% for at least 6 months. The results from these studies are consistent with those reported for the US controlled clinical trial.
Blood Pressure Increases
In a 4-month clinical study, 24-hour ambulatory blood pressure monitoring (ABPM) was conducted on 225 patients. ABPM was conducted at baseline and at Week 16 of testosterone gel 1% therapy. A total of 113 patients had acceptable ABPM recordings at both baseline and Week 16 and were at least 85% compliant with study drug. In that group, the mean change in 24-hour systolic blood pressure (BP) and diastolic BP from baseline to end-of-treatment at Week 16 (n=113) was 2.7 mm Hg (95% CI 0.7, 4.8) and 1.1 mm Hg (95% CI -0.1, 2.3), respectively. In patients with a history of hypertension who were receiving antihypertensive therapy, the mean ABPM systolic and diastolic BP increased by 1.9 mm Hg [95% CI -1.4, 5.2] and 0.3 mm Hg [95% CI -1.6, 2.2], respectively [n=55]). In patients with no history of hypertension, the mean systolic and diastolic blood pressure increased by 2.2 mm Hg [95% CI -0.4, 4.9] and 1.1 mm Hg [95% CI -0.4, 2.7], respectively [n=56].
3 patients (2.7%) on testosterone gel 1%, all of whom were receiving antihypertensive medications at baseline, either started new antihypertensive medications (n=3) or had their antihypertensive medication regimen adjusted (n=0) during the ABPM study.
Of the 225 patients in the ABPM study who used testosterone gel 1%, 6 patients (2.7%) were reported to have either an adverse reaction of hypertension (6 patients, 2.7%) or increased blood pressure (0 patients, 0.0%).
Cardiovascular Outcomes
TRAVERSE was a randomized, double-blind, cardiovascular outcomes study to assess the cardiovascular (CV) safety of topical testosterone gel compared to placebo in 5,198 hypogonadal men aged 45 to 80 years with a history of CV disease or with multiple CV risk factors. The primary outcome was the incidence of the composite endpoint of major adverse cardiovascular events (MACE), consisting of CV death, non-fatal myocardial infarction (MI), and non-fatal stroke.
The mean duration of therapy was approximately 22 months. The mean duration of follow-up was 33 months. Approximately 61% of all patients discontinued topical testosterone gel or placebo therapy.
The mean patient age (±SD) was 63.3 (7.9) years, with 2,452 patients aged 65 years or more (47%); 2,847 (about 55%) patients had pre-existing cardiovascular disease, whereas 2,357 patients (about 45%) had an elevated cardiovascular risk at baseline, and mean BMI was 35kg/m2. Approximately 80% of patients were White, 17% were Black, and 3% were of other races or ethnic groups. Approximately 69%, 84%, and 93% had diabetes mellitus, hyperlipidemia, and hypertension, respectively.
The mean serum testosterone concentration at baseline in patients receiving topical testosterone gel was
220.4 ng/dL (n=2,596). The mean serum testosterone concentrations at 12 months, 24 months, 36 months, and 48 months in patients receiving topical testosterone gel were 440.5 ng/dL (n=1,683), 420.9 ng/dl (n=1,125), 428.7 ng/dL (n=731), and 365.2 ng/dL (n=220), respectively.
For patients treated with topical testosterone gel, the incidence of MACE was 7.0% (n=182 events) and for those receiving placebo, the incidence of MACE was 7.3% (n=190 events). The study demonstrated non-inferiority of topical testosterone gel versus placebo because the upper bound of 95% CI was less than the pre-specified risk margin, of 1.5 for MACE (Hazard Ratio 0.96 [95% CI: 0.78, 1.17]).
Additional Adverse Reactions Reported in TRAVERSE
Additional adverse reactions reported in TRAVERSE at an incidence rate >2% in either treatment group and greater in topical testosterone gel versus placebo included: nonfatal arrythmias warranting intervention (5.2% vs 3.3%), atrial fibrillation (3.5% vs 2.4%), acute kidney injury (2.3% vs 1.5%) and bone fracture (3.5% vs 2.5%). For the adverse reaction of bone fracture, each event was adjudicated by clinical review.